FDA Approves Zepbound for Sleep Apnea Treatment

The FDA has approved Zepbound, a weight-loss drug by Eli Lilly, as the first medicine to treat obstructive sleep apnea (OSA). This approval marks a significant advancement for patients with moderate to severe OSA who are also obese, potentially reducing the need for CPAP machines or surgery. Zepbound works by activating hormones that decrease appetite and food intake, contributing to weight loss and subsequently improving OSA symptoms. Clinical trials showed a 63% reduction in restricted breathing and significant weight loss in participants, leading to fewer sleep interruptions. This decision opens up a large market for Eli Lilly, as sleep apnea affects approximately 30 million adults in the U.S. and one billion globally. Shares of Eli Lilly rose following the announcement, as the approval could also encourage insurers to cover the drug despite its high cost.